About this item
Product details
Rezna (Resmetirom) 60 mg is a novel, once-daily oral medication specifically designed for the treatment of non-alcoholic steatohepatitis (NASH), now known as metabolic dysfunction-associated steatohepatitis (MASH), in adult patients with moderate to advanced liver fibrosis. Manufactured by Nabiqasim, it is the first FDA-approved therapy for this serious liver condition and represents a significant advancement in hepatology. Targeted MASH Therapy: The first FDA-approved oral medication specifically indicated to treat MASH (NASH) with moderate to advanced liver fibrosis. Dual-Action Liver Improvement: Clinically proven to improve key markers: reduction of liver fat (steatosis) and resolution of MASH (reduction of inflammation and ballooning) without worsening of fibrosis. Fibrosis Impact: May help to slow or halt the progression of liver fibrosis, reducing the risk of cirrhosis and liver failure. Thyroid Hormone Receptor-Beta Agonist: Works by selectively activating the thyroid hormone receptor beta in the liver, which increases hepatic fat metabolism and reduces lipotoxicity. Composition Each film coated tablet contains: Resmetirom: 60 mg Directions for Use As directed by the doctor.
- Medicines
- 14 Film Coated Tablets
- 1 variant
- Protected Dastak checkout
Know before you buy
Specifications
- Department
- Health
- Subcategory
- Medicines
- Brand
- Nabiqasim
- SKU
- 08964003525163
- Variant
- 14 Film Coated Tablets
- Tags
- Medicine, Resmetirom
- Condition
- New
Customer feedback
Ratings & reviews
For help with a purchase, open your orders or contact Dastak support.
